Cargando…

Biomarkers in Prostate-Specific Membrane Antigen Theranostics

Theranostics of prostate cancer (PC) represents a growing area of development of imaging agents and targeted radionuclide therapeutics against a major target, prostate specific membrane antigen (PSMA). In view of the encouraging efficacy from the use of (177)Lu and other radionuclides in metastatic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vlachostergios, Panagiotis J., Zachos, Ioannis, Tzortzis, Vassilios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235046/ https://www.ncbi.nlm.nih.gov/pubmed/34207069 http://dx.doi.org/10.3390/diagnostics11061108

Ejemplares similares

Upper Tract Urothelial Carcinoma: A Rare Malignancy with Distinct Immuno-Genomic Features in the Era of Precision-Based Therapies
por: Evmorfopoulos, Konstantinos, et al.
Publicado: (2023)

Expression of Fibroblast Activation Protein Is Enriched in Neuroendocrine Prostate Cancer and Predicts Worse Survival
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2022)

Characterization of a miRNA Signature with Enhanced Diagnostic and Prognostic Power for Patients with Bladder Carcinoma
por: Samara, Maria, et al.
Publicado: (2023)

Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer
por: Plichta, Kristin A., et al.
Publicado: (2021)

Hypoxia-Inducible Factor-2-Altered Urothelial Carcinoma: Clinical and Genomic Features
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2022)

Radiofrequency-assisted, laparoscopic, clampless partial nephrectomy in patients with low-complexity small renal tumors: A retrospective cohort study
por: Zachos, Ioannis, et al.
Publicado: (2023)

Complete Vascular Replacement of the Infrarenal Inferior Vena Cava and Abdominal Aorta during Post-Chemotherapy Retroperitoneal Lymph Node Dissection for a Non-Seminomatous Germ Cell Tumor
por: Evmorfopoulos, Konstantinos, et al.
Publicado: (2023)

Early mRNA Expression of Neuroendocrine Differentiation Signals Predicts Recurrence After Radical Prostatectomy: A Transcriptomic Analysis
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2021)

Prostate-Specific Membrane Antigen Expression in Meningioma: A Promising Theranostic Target
por: Tubre, Teddi, et al.
Publicado: (2022)

Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2021)

Rationale for Prostate-Specific-Membrane-Antigen-Targeted Radionuclide Theranostic Applied to Metastatic Clear Cell Renal Carcinoma
por: Giraudet, Anne Laure, et al.
Publicado: (2023)

Current Options for Second-Line Systemic Therapy in Metastatic Renal Cell Carcinoma
por: Mitsogiannis, Iraklis C., et al.
Publicado: (2022)

Clear-cell renal cell carcinoma single urinary bladder metastasis: a case report and review of the literature
por: Zachos, Ioannis, et al.
Publicado: (2022)

DNA Repair Gene Polymorphisms and Susceptibility to Urothelial Carcinoma in a Southeastern European Population
por: Samara, Maria, et al.
Publicado: (2021)

Surface Modification of Liposomes by a Lipopolymer Targeting Prostate Specific Membrane Antigen for Theranostic Delivery in Prostate Cancer
por: Yari, Hooman, et al.
Publicado: (2019)

Mixed epithelial and stromal tumor—adult cystic nephroma of the kidney: a case report with immunohistochemical analysis
por: Karasavvidou, Foteini, et al.
Publicado: (2022)

Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent
por: Chatalic, Kristell L.S., et al.
Publicado: (2016)

Lutetium-177 prostate-specific membrane antigen-617 theranostics: New therapeutic hope in metastatic castrate-resistant prostate cancer?
por: Ranjan, Satish Kumar
Publicado: (2020)

Prostate-specific Membrane Antigen Imaging in Recurrent Medullary Thyroid Cancer: A New Theranostic Tracer in the Offing?
por: Arora, Saurabh, et al.
Publicado: (2018)

Health-Related Quality of Life Assessment in Daily Urologic Practice: A Survey of Greek Urologists
por: Mitsogiannis, Iraklis C, et al.
Publicado: (2022)

MicroRNAs as Biomarkers for Diagnosis, Prognosis and Theranostics in Prostate Cancer
por: Bertoli, Gloria, et al.
Publicado: (2016)

Tumor Sink Effect with Prostate-Specific Membrane Antigen-Targeted Theranostics in Patients with Metastatic Castration-Resistant Prostate Cancer: Intra-Individual Evaluations
por: Burgard, Caroline, et al.
Publicado: (2023)

Updates of prostate cancer staging: Prostate-specific membrane antigen
por: Sathianathen, Niranjan J, et al.
Publicado: (2016)

The Role of the Small Ubiquitin-Related Modifier (SUMO) Pathway in Prostate Cancer
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2012)

Prostate-Specific Membrane Antigen-Based Therapeutics
por: Akhtar, Naveed H., et al.
Publicado: (2012)

Expression of Neutral Endopeptidase, Endothelin-1, and Nuclear Factor Kappa B in Prostate Cancer: Interrelations and Associations with Prostate-Specific Antigen Recurrence after Radical Prostatectomy
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2012)

Theranostic Biomarkers for Schizophrenia
por: Nikolac Perkovic, Matea, et al.
Publicado: (2017)

PSMA-GCK01: A Generator-Based (99m)Tc/(188)Re Theranostic Ligand for the Prostate-Specific Membrane Antigen
por: Cardinale, Jens, et al.
Publicado: (2023)

Co-expression and impact of prostate specific membrane antigen and prostate specific antigen in prostatic pathologies
por: Ben Jemaa , Awatef, et al.
Publicado: (2010)

Deep Membrane Proteome Profiling Reveals Overexpression of Prostate-Specific Membrane Antigen (PSMA) in High-Risk Human Paraganglioma and Pheochromocytoma, Suggesting New Theranostic Opportunity
por: Vit, Ondrej, et al.
Publicado: (2021)

Management of Patients with Liver Cirrhosis and Invasive Bladder Cancer: A Case-series
por: Zachos, Ioannis, et al.
Publicado: (2019)

Combined DNA repair defects in testicular metastasis from prostate cancer sensitize to immune checkpoint blockade
por: Vlachostergios, Panagiotis J.
Publicado: (2021)

Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers
por: Filella, Xavier, et al.
Publicado: (2016)

Immune-based treatment re-challenge in renal cell carcinoma: A systematic review and meta-analysis
por: Papathanassiou, Maria, et al.
Publicado: (2022)

Current status of theranostics in prostate cancer
por: Virgolini, Irene, et al.
Publicado: (2017)

Prostate-specific membrane antigen-mediated theragnostics in prostate cancer
por: Jeong, Seung-hwan, et al.
Publicado: (2021)

Incidental prostate-specific membrane antigen-avid meningioma detected on (68)Ga–prostate-specific membrane antigen PET/CT
por: Jiang, James Yuheng, et al.
Publicado: (2021)

Biomolecule-functionalized nanoformulations for prostate cancer theranostics
por: Pranav, et al.
Publicado: (2022)

Incidental prostate-specific membrane antigen-avid glioblastoma detected on (68)Ga–prostate-specific membrane antigen PET/CT
por: Jiang, James Yuheng, et al.
Publicado: (2022)

Targeting Neuroendocrine Prostate Cancer: Molecular and Clinical Perspectives
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_3pc76lgofoa5nc0o2889kbr90p